King Luther Capital Management Corp Grows Stock Position in Amgen Inc. $AMGN

King Luther Capital Management Corp grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 515,668 shares of the medical research company’s stock after buying an additional 6,510 shares during the period. King Luther Capital Management Corp’s holdings in Amgen were worth $168,783,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Capital World Investors raised its position in shares of Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after purchasing an additional 1,935,876 shares during the last quarter. Vanguard Group Inc. grew its position in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the last quarter. National Bank of Canada FI increased its stake in Amgen by 237.7% during the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after purchasing an additional 863,216 shares in the last quarter. Van ECK Associates Corp raised its holdings in shares of Amgen by 71.8% in the third quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock worth $383,254,000 after buying an additional 567,400 shares during the last quarter. Finally, Fisher Asset Management LLC raised its holdings in shares of Amgen by 91.6% in the third quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock worth $221,607,000 after buying an additional 375,463 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Down 1.0%

Shares of Amgen stock opened at $335.94 on Wednesday. The stock has a market cap of $181.30 billion, a PE ratio of 23.38, a price-to-earnings-growth ratio of 3.41 and a beta of 0.44. The firm has a fifty day moving average price of $343.92 and a 200 day moving average price of $345.13. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts predict that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. Amgen’s dividend payout ratio is presently 70.15%.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company boosted their price objective on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Mizuho raised their target price on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Finally, Leerink Partners reissued a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $355.19.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.